{"id":5693,"date":"2024-04-25T07:15:32","date_gmt":"2024-04-25T12:15:32","guid":{"rendered":"https:\/\/nanostherapeutics.com\/?p=5693"},"modified":"2025-06-27T11:19:33","modified_gmt":"2025-06-27T16:19:33","slug":"nanoscope-therapeutics-enhances-mutation-independent-retinal-gene-therapy-programs-with-appointment-of-allen-c-ho-md-as-chief-medical-advisor","status":"publish","type":"post","link":"https:\/\/nanostherapeutics.com\/es\/2024\/04\/25\/nanoscope-therapeutics-enhances-mutation-independent-retinal-gene-therapy-programs-with-appointment-of-allen-c-ho-md-as-chief-medical-advisor\/","title":{"rendered":"Nanoscope Therapeutics mejora los programas de terapia g\u00e9nica retiniana independiente de mutaciones con el nombramiento de Allen C. Ho, MD, como asesor m\u00e9dico jefe"},"content":{"rendered":"<div class=\"col-sm-8 col-vcenter col-xs-12\">\n<div class=\"col-sm-8 col-vcenter col-xs-12\">\n<div class=\"col-sm-8 col-vcenter col-xs-12\">\n<h1><\/h1>\n<\/div>\n<\/div>\n<\/div>\n<article class=\"news-release inline-gallery-template\">\n<section class=\"release-body container\">\n<div class=\"row\">\n<div class=\"col-lg-10 col-lg-offset-1\">\n<p><span class=\"legendSpanClass\"><span class=\"xn-location\">DALLAS<\/span><\/span>, <span class=\"legendSpanClass\"><span class=\"xn-chron\">25 de abril de 2024<\/span><\/span>\u00a0 \u2014 <a href=\"http:\/\/nanostherapeutics.com\/es\/\" target=\"_blank\" rel=\"nofollow noopener\">Nanoscope Therapeutics, Inc.<\/a>, una empresa de biotecnolog\u00eda en etapa cl\u00ednica que desarrolla terapias gen\u00e9ticas para enfermedades degenerativas de la retina, anunci\u00f3 hoy el nombramiento de <span class=\"xn-person\">Allen C.Ho<\/span>, MD, FACS, FASRS, como asesor m\u00e9dico jefe, donde ayudar\u00e1 a definir la estrategia de desarrollo de terapias independientes de las mutaciones gen\u00e9ticas. El Dr. Ho es cirujano asistente y director de investigaci\u00f3n de retina en Wills Eye Hospital y codirector del servicio de retina de Wills Eye Hospital.<\/p>\n<p>\u201cEstamos encantados de contar con el Dr. <span class=\"xn-person\">Allen C.Ho<\/span> \u201dSe unir\u00e1 a Nanoscope como Asesor M\u00e9dico Jefe\u201d, dijo. <span class=\"xn-person\">Sulagna Bhattacharya<\/span>, cofundador y director ejecutivo de Nanoscope. \u201cComo especialista en retina de renombre mundial y l\u00edder en tratamientos innovadores para enfermedades de la retina, su perspectiva ser\u00e1 invaluable para Nanoscope. MCO-010 tiene el potencial de ser la primera terapia g\u00e9nica disponible para pacientes con retinosis pigmentaria (RP) avanzada, y las contribuciones del Dr. Ho ayudar\u00e1n a garantizar ese potencial. Tambi\u00e9n esperamos incorporar su perspectiva al desarrollo de MCO-010 para la enfermedad de Stargardt, bas\u00e1ndonos en los prometedores resultados de nuestro ensayo cl\u00ednico de fase 2 STARLIGHT\u201d.\u201d<\/p>\n<p>\u201cEspero trabajar a\u00fan m\u00e1s de cerca con los miembros del equipo y el liderazgo de Nanoscope, quienes han estado trabajando en estrategias optogen\u00e9ticas sensibles a la luz ambiental para enfermedades de la retina durante la \u00faltima d\u00e9cada\u201d, dijo el Dr. Ho. \u201cEl reciente lanzamiento de su Fase de 2 a\u00f1os <span class=\"xn-money\">2b<\/span> Los datos del ensayo RESTORE representan un momento importante para la comunidad oftalmol\u00f3gica especializada en retina, y me complace contribuir a la administraci\u00f3n de este tratamiento transformador para quienes padecen retinosis pigmentaria avanzada. Asimismo, me entusiasma el desarrollo de Nanoscope y el potencial traslacional de la administraci\u00f3n l\u00e1ser no viral guiada por im\u00e1genes de MCO-020 para mejorar la visi\u00f3n en pacientes con atrofia geogr\u00e1fica secundaria a la degeneraci\u00f3n macular asociada a la edad.<\/p>\n<p><b><span class=\"xn-person\">Allen C.Ho<\/span>, MD, FACS, FASRS<br class=\"dnr\" \/><\/b><span class=\"xn-person\">Allen C.Ho<\/span> MD, FACS es cirujano tratante y director de investigaci\u00f3n de retina y codirector del servicio de retina de Wills Eye Hospital, profesor de oftalmolog\u00eda en <span class=\"xn-org\">Universidad Thomas Jefferson<\/span> y socio de Mid Atlantic Retina. Mantiene intereses especiales en enfermedades maculares, retinopat\u00eda diab\u00e9tica, enfermedades quir\u00fargicas de la retina y ensayos cl\u00ednicos que investigan nuevos tratamientos para enfermedades vitreorretinianas, incluidas terapias gen\u00e9ticas y celulares y nuevos dispositivos y t\u00e9cnicas de administraci\u00f3n de f\u00e1rmacos quir\u00fargicos. Su experiencia incluye investigaci\u00f3n colaborativa traslacional y de ensayos cl\u00ednicos con experiencia en dise\u00f1o de estudios, pruebas metodol\u00f3gicas, an\u00e1lisis de datos, instrumentaci\u00f3n quir\u00fargica y desarrollo de procedimientos, ejecuci\u00f3n y comunicaci\u00f3n de estos estudios y sus resultados, y comercializaci\u00f3n centrada en el acceso de los pacientes a la atenci\u00f3n. El Dr. Ho ha formado parte del Panel de Dispositivos Oft\u00e1lmicos de la FDA de EE. UU., del Grupo de Trabajo de Innovaci\u00f3n de la Academia Estadounidense de Oftalmolog\u00eda (AAO), del Comit\u00e9 de Evaluaci\u00f3n de Tecnolog\u00eda de Retina Oft\u00e1lmica de la AAO, del Grupo de Medidas de Retina de la AAO, del Comit\u00e9 de Registro IRIS de la AAO y es l\u00edder de Eyecelerator, el mayor laboratorio oft\u00e1lmico. encuentro de innovaci\u00f3n en el mundo.<\/p>\n<p><b>Acerca de Nanoscope Therapeutics, Inc.<br class=\"dnr\" \/><\/b>Nanoscope Therapeutics est\u00e1 desarrollando terapias optogen\u00e9ticas independientes del gen que restauran la visi\u00f3n para millones de pacientes ciegos por enfermedades retinianas hereditarias para las que no existe cura. El principal f\u00e1rmaco de la compa\u00f1\u00eda, MCO-010, inform\u00f3 recientemente los resultados preliminares de la fase RESTORE. <span class=\"xn-money\">2b<\/span>\/3 ensayo cl\u00ednico multic\u00e9ntrico, aleatorizado, doble enmascarado y controlado de forma simulada en los EE. UU. para la retinosis pigmentaria (<a href=\"https:\/\/c212.net\/c\/link\/?t=0&l=en&o=4149309-1&h=2930639158&u=https%3A%2F%2Fclinicaltrials.gov%2Fct2%2Fshow%2FNCT04945772%3Fterm%3DNanoscope%26draw%3D2&a=NCT04945772\" target=\"_blank\" rel=\"nofollow noopener\">NCT04945772<\/a>). La compa\u00f1\u00eda tambi\u00e9n complet\u00f3 recientemente su visita de fin de estudio para el ensayo de fase 2 STARLIGHT de la terapia MCO-010 para pacientes con enfermedad de Stargardt (<a href=\"https:\/\/c212.net\/c\/link\/?t=0&l=en&o=4149309-1&h=4035518438&u=https%3A%2F%2Fclinicaltrials.gov%2Fct2%2Fshow%2FNCT05417126%3Fterm%3Dnanoscope%26draw%3D2%26rank%3D3&a=NCT05417126\" target=\"_blank\" rel=\"nofollow noopener\">NCT05417126<\/a>). MCO-010 ha recibido designaciones de v\u00eda r\u00e1pida de la FDA y designaciones de medicamento hu\u00e9rfano de la FDA tanto para la retinitis pigmentosa como para la enfermedad de Stargardt. Los activos precl\u00ednicos incluyen la terapia g\u00e9nica MCO-020 administrada con l\u00e1ser no viral para la atrofia geogr\u00e1fica. Para obtener m\u00e1s informaci\u00f3n, visite <a href=\"https:\/\/nanostherapeutics.com\/es\/\" target=\"_blank\" rel=\"nofollow noopener\">www.nanostherapeutics.com<\/a> y s\u00edguelos <a href=\"https:\/\/www.linkedin.com\/company\/nanoscope-therapeutics-inc\" target=\"_blank\" rel=\"nofollow noopener\">LinkedIn<\/a>.<\/p>\n<p><b>Contacto de inversores:<\/b><br class=\"dnr\" \/>Socios Argot<br class=\"dnr\" \/>212-600-1902<br class=\"dnr\" \/><a href=\"mailto:Nanoscope@argotpartners.com\" target=\"_blank\" rel=\"nofollow noopener\">PR@nanostherapeutics.com<\/a><\/p>\n<p>FUENTE Terap\u00e9utica del Nanoscopio<\/p>\n<\/div>\n<\/div>\n<\/section>\n<\/article>","protected":false},"excerpt":{"rendered":"<p>DALLAS, April 25, 2024\u00a0 \u2014 Nanoscope Therapeutics, Inc., a clinical-stage biotechnology company developing gene therapies for retinal degenerative diseases, announced today the appointment of Allen C. Ho, MD, FACS, FASRS, as Chief Medical Advisor, where he will help define the strategy of developing the gene mutation-agnostic therapies. Dr. Ho is Attending Surgeon and Director of [&hellip;]<\/p>\n","protected":false},"author":6,"featured_media":5694,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_exactmetrics_skip_tracking":false,"_exactmetrics_sitenote_active":false,"_exactmetrics_sitenote_note":"","_exactmetrics_sitenote_category":0,"footnotes":"","_links_to":"","_links_to_target":""},"categories":[13,8],"tags":[],"class_list":["post-5693","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-home-page","category-nanoscope-press-release"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.6 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Nanoscope Therapeutics Enhances Mutation-Independent Retinal Gene Therapy Programs with Appointment of Allen C. Ho, MD, as Chief Medical Advisor - Nanoscope Therapeutics<\/title>\n<meta name=\"description\" content=\"Our multi-characteristic opsin (MCO) platform is the first to demonstrate an ability to restore vision to retinal disease patients with severe vision loss in clincial trials. Nanoscope has developed MCO-010, the first and only broad spectrum, fast response and ultra-sensitive optogenetic technology for vision restoration that is gene-agnostic.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/nanostherapeutics.com\/es\/2024\/04\/25\/nanoscope-therapeutics-enhances-mutation-independent-retinal-gene-therapy-programs-with-appointment-of-allen-c-ho-md-as-chief-medical-advisor\/\" \/>\n<meta property=\"og:locale\" content=\"es_MX\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Nanoscope Therapeutics Enhances Mutation-Independent Retinal Gene Therapy Programs with Appointment of Allen C. Ho, MD, as Chief Medical Advisor - Nanoscope Therapeutics\" \/>\n<meta property=\"og:description\" content=\"Our multi-characteristic opsin (MCO) platform is the first to demonstrate an ability to restore vision to retinal disease patients with severe vision loss in clincial trials. Nanoscope has developed MCO-010, the first and only broad spectrum, fast response and ultra-sensitive optogenetic technology for vision restoration that is gene-agnostic.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/nanostherapeutics.com\/es\/2024\/04\/25\/nanoscope-therapeutics-enhances-mutation-independent-retinal-gene-therapy-programs-with-appointment-of-allen-c-ho-md-as-chief-medical-advisor\/\" \/>\n<meta property=\"og:site_name\" content=\"Nanoscope Therapeutics\" \/>\n<meta property=\"article:published_time\" content=\"2024-04-25T12:15:32+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-06-27T16:19:33+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2024\/04\/NSCOPE_LI_AllenHo_V3REV.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1200\" \/>\n\t<meta property=\"og:image:height\" content=\"627\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Nanoscope Therapeutics\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:image\" content=\"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2024\/04\/NSCOPE_LI_AllenHo_V3REV.jpg\" \/>\n<meta name=\"twitter:creator\" content=\"@NSTherapeutics\" \/>\n<meta name=\"twitter:site\" content=\"@NSTherapeutics\" \/>\n<meta name=\"twitter:label1\" content=\"Escrito por\" \/>\n\t<meta name=\"twitter:data1\" content=\"Nanoscope Therapeutics\" \/>\n\t<meta name=\"twitter:label2\" content=\"Tiempo de lectura\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutos\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2024\\\/04\\\/25\\\/nanoscope-therapeutics-enhances-mutation-independent-retinal-gene-therapy-programs-with-appointment-of-allen-c-ho-md-as-chief-medical-advisor\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2024\\\/04\\\/25\\\/nanoscope-therapeutics-enhances-mutation-independent-retinal-gene-therapy-programs-with-appointment-of-allen-c-ho-md-as-chief-medical-advisor\\\/\"},\"author\":{\"name\":\"Nanoscope Therapeutics\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#\\\/schema\\\/person\\\/5aeedc9aef0946fe8f96f98f7b1808a2\"},\"headline\":\"Nanoscope Therapeutics Enhances Mutation-Independent Retinal Gene Therapy Programs with Appointment of Allen C. Ho, MD, as Chief Medical Advisor\",\"datePublished\":\"2024-04-25T12:15:32+00:00\",\"dateModified\":\"2025-06-27T16:19:33+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2024\\\/04\\\/25\\\/nanoscope-therapeutics-enhances-mutation-independent-retinal-gene-therapy-programs-with-appointment-of-allen-c-ho-md-as-chief-medical-advisor\\\/\"},\"wordCount\":586,\"publisher\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2024\\\/04\\\/25\\\/nanoscope-therapeutics-enhances-mutation-independent-retinal-gene-therapy-programs-with-appointment-of-allen-c-ho-md-as-chief-medical-advisor\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/nanostherapeutics.com\\\/wp-content\\\/uploads\\\/2024\\\/04\\\/NSCOPE_LI_AllenHo_V3REV.jpg\",\"articleSection\":[\"Home Page\",\"Nanoscope Press Release\"],\"inLanguage\":\"es\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2024\\\/04\\\/25\\\/nanoscope-therapeutics-enhances-mutation-independent-retinal-gene-therapy-programs-with-appointment-of-allen-c-ho-md-as-chief-medical-advisor\\\/\",\"url\":\"https:\\\/\\\/nanostherapeutics.com\\\/2024\\\/04\\\/25\\\/nanoscope-therapeutics-enhances-mutation-independent-retinal-gene-therapy-programs-with-appointment-of-allen-c-ho-md-as-chief-medical-advisor\\\/\",\"name\":\"Nanoscope Therapeutics Enhances Mutation-Independent Retinal Gene Therapy Programs with Appointment of Allen C. Ho, MD, as Chief Medical Advisor - Nanoscope Therapeutics\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2024\\\/04\\\/25\\\/nanoscope-therapeutics-enhances-mutation-independent-retinal-gene-therapy-programs-with-appointment-of-allen-c-ho-md-as-chief-medical-advisor\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2024\\\/04\\\/25\\\/nanoscope-therapeutics-enhances-mutation-independent-retinal-gene-therapy-programs-with-appointment-of-allen-c-ho-md-as-chief-medical-advisor\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/nanostherapeutics.com\\\/wp-content\\\/uploads\\\/2024\\\/04\\\/NSCOPE_LI_AllenHo_V3REV.jpg\",\"datePublished\":\"2024-04-25T12:15:32+00:00\",\"dateModified\":\"2025-06-27T16:19:33+00:00\",\"description\":\"Our multi-characteristic opsin (MCO) platform is the first to demonstrate an ability to restore vision to retinal disease patients with severe vision loss in clincial trials. Nanoscope has developed MCO-010, the first and only broad spectrum, fast response and ultra-sensitive optogenetic technology for vision restoration that is gene-agnostic.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2024\\\/04\\\/25\\\/nanoscope-therapeutics-enhances-mutation-independent-retinal-gene-therapy-programs-with-appointment-of-allen-c-ho-md-as-chief-medical-advisor\\\/#breadcrumb\"},\"inLanguage\":\"es\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/nanostherapeutics.com\\\/2024\\\/04\\\/25\\\/nanoscope-therapeutics-enhances-mutation-independent-retinal-gene-therapy-programs-with-appointment-of-allen-c-ho-md-as-chief-medical-advisor\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2024\\\/04\\\/25\\\/nanoscope-therapeutics-enhances-mutation-independent-retinal-gene-therapy-programs-with-appointment-of-allen-c-ho-md-as-chief-medical-advisor\\\/#primaryimage\",\"url\":\"https:\\\/\\\/nanostherapeutics.com\\\/wp-content\\\/uploads\\\/2024\\\/04\\\/NSCOPE_LI_AllenHo_V3REV.jpg\",\"contentUrl\":\"https:\\\/\\\/nanostherapeutics.com\\\/wp-content\\\/uploads\\\/2024\\\/04\\\/NSCOPE_LI_AllenHo_V3REV.jpg\",\"width\":1200,\"height\":627},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2024\\\/04\\\/25\\\/nanoscope-therapeutics-enhances-mutation-independent-retinal-gene-therapy-programs-with-appointment-of-allen-c-ho-md-as-chief-medical-advisor\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/nanostherapeutics.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Nanoscope Therapeutics Enhances Mutation-Independent Retinal Gene Therapy Programs with Appointment of Allen C. Ho, MD, as Chief Medical Advisor\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#website\",\"url\":\"https:\\\/\\\/nanostherapeutics.com\\\/\",\"name\":\"Nanoscope Therapeutics\",\"description\":\"Bringing Back the Light of Hope\",\"publisher\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#organization\"},\"alternateName\":\"Nanoscope Therapeutics\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/nanostherapeutics.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"es\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#organization\",\"name\":\"Nanoscope Therapeutics, Inc\",\"alternateName\":\"Nanoscope Therapeutics\",\"url\":\"https:\\\/\\\/nanostherapeutics.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/nanostherapeutics.com\\\/wp-content\\\/uploads\\\/2025\\\/03\\\/NSCOPE_Logo_Stack_2Color_512.png\",\"contentUrl\":\"https:\\\/\\\/nanostherapeutics.com\\\/wp-content\\\/uploads\\\/2025\\\/03\\\/NSCOPE_Logo_Stack_2Color_512.png\",\"width\":512,\"height\":435,\"caption\":\"Nanoscope Therapeutics, Inc\"},\"image\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/x.com\\\/NSTherapeutics\",\"https:\\\/\\\/www.linkedin.com\\\/company\\\/nanoscope\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#\\\/schema\\\/person\\\/5aeedc9aef0946fe8f96f98f7b1808a2\",\"name\":\"Nanoscope Therapeutics\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Nanoscope Therapeutics refuerza sus programas de terapia g\u00e9nica retiniana independiente de mutaciones con el nombramiento del Dr. Allen C. Ho como asesor m\u00e9dico principal.","description":"Nuestra plataforma de opsina multicaracter\u00edstica (MCO) es la primera en demostrar, en ensayos cl\u00ednicos, la capacidad de restaurar la visi\u00f3n en pacientes con enfermedades retinianas y p\u00e9rdida visual severa. Nanoscope ha desarrollado MCO-010, la primera y \u00fanica tecnolog\u00eda optogen\u00e9tica de amplio espectro, respuesta r\u00e1pida y ultrasensible para la restauraci\u00f3n de la visi\u00f3n, independiente del gen.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/nanostherapeutics.com\/es\/2024\/04\/25\/nanoscope-therapeutics-enhances-mutation-independent-retinal-gene-therapy-programs-with-appointment-of-allen-c-ho-md-as-chief-medical-advisor\/","og_locale":"es_MX","og_type":"article","og_title":"Nanoscope Therapeutics Enhances Mutation-Independent Retinal Gene Therapy Programs with Appointment of Allen C. Ho, MD, as Chief Medical Advisor - Nanoscope Therapeutics","og_description":"Our multi-characteristic opsin (MCO) platform is the first to demonstrate an ability to restore vision to retinal disease patients with severe vision loss in clincial trials. Nanoscope has developed MCO-010, the first and only broad spectrum, fast response and ultra-sensitive optogenetic technology for vision restoration that is gene-agnostic.","og_url":"https:\/\/nanostherapeutics.com\/es\/2024\/04\/25\/nanoscope-therapeutics-enhances-mutation-independent-retinal-gene-therapy-programs-with-appointment-of-allen-c-ho-md-as-chief-medical-advisor\/","og_site_name":"Nanoscope Therapeutics","article_published_time":"2024-04-25T12:15:32+00:00","article_modified_time":"2025-06-27T16:19:33+00:00","og_image":[{"width":1200,"height":627,"url":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2024\/04\/NSCOPE_LI_AllenHo_V3REV.jpg","type":"image\/jpeg"}],"author":"Nanoscope Therapeutics","twitter_card":"summary_large_image","twitter_image":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2024\/04\/NSCOPE_LI_AllenHo_V3REV.jpg","twitter_creator":"@NSTherapeutics","twitter_site":"@NSTherapeutics","twitter_misc":{"Escrito por":"Nanoscope Therapeutics","Tiempo de lectura":"3 minutos"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/nanostherapeutics.com\/2024\/04\/25\/nanoscope-therapeutics-enhances-mutation-independent-retinal-gene-therapy-programs-with-appointment-of-allen-c-ho-md-as-chief-medical-advisor\/#article","isPartOf":{"@id":"https:\/\/nanostherapeutics.com\/2024\/04\/25\/nanoscope-therapeutics-enhances-mutation-independent-retinal-gene-therapy-programs-with-appointment-of-allen-c-ho-md-as-chief-medical-advisor\/"},"author":{"name":"Nanoscope Therapeutics","@id":"https:\/\/nanostherapeutics.com\/#\/schema\/person\/5aeedc9aef0946fe8f96f98f7b1808a2"},"headline":"Nanoscope Therapeutics Enhances Mutation-Independent Retinal Gene Therapy Programs with Appointment of Allen C. Ho, MD, as Chief Medical Advisor","datePublished":"2024-04-25T12:15:32+00:00","dateModified":"2025-06-27T16:19:33+00:00","mainEntityOfPage":{"@id":"https:\/\/nanostherapeutics.com\/2024\/04\/25\/nanoscope-therapeutics-enhances-mutation-independent-retinal-gene-therapy-programs-with-appointment-of-allen-c-ho-md-as-chief-medical-advisor\/"},"wordCount":586,"publisher":{"@id":"https:\/\/nanostherapeutics.com\/#organization"},"image":{"@id":"https:\/\/nanostherapeutics.com\/2024\/04\/25\/nanoscope-therapeutics-enhances-mutation-independent-retinal-gene-therapy-programs-with-appointment-of-allen-c-ho-md-as-chief-medical-advisor\/#primaryimage"},"thumbnailUrl":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2024\/04\/NSCOPE_LI_AllenHo_V3REV.jpg","articleSection":["Home Page","Nanoscope Press Release"],"inLanguage":"es"},{"@type":"WebPage","@id":"https:\/\/nanostherapeutics.com\/2024\/04\/25\/nanoscope-therapeutics-enhances-mutation-independent-retinal-gene-therapy-programs-with-appointment-of-allen-c-ho-md-as-chief-medical-advisor\/","url":"https:\/\/nanostherapeutics.com\/2024\/04\/25\/nanoscope-therapeutics-enhances-mutation-independent-retinal-gene-therapy-programs-with-appointment-of-allen-c-ho-md-as-chief-medical-advisor\/","name":"Nanoscope Therapeutics refuerza sus programas de terapia g\u00e9nica retiniana independiente de mutaciones con el nombramiento del Dr. Allen C. Ho como asesor m\u00e9dico principal.","isPartOf":{"@id":"https:\/\/nanostherapeutics.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/nanostherapeutics.com\/2024\/04\/25\/nanoscope-therapeutics-enhances-mutation-independent-retinal-gene-therapy-programs-with-appointment-of-allen-c-ho-md-as-chief-medical-advisor\/#primaryimage"},"image":{"@id":"https:\/\/nanostherapeutics.com\/2024\/04\/25\/nanoscope-therapeutics-enhances-mutation-independent-retinal-gene-therapy-programs-with-appointment-of-allen-c-ho-md-as-chief-medical-advisor\/#primaryimage"},"thumbnailUrl":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2024\/04\/NSCOPE_LI_AllenHo_V3REV.jpg","datePublished":"2024-04-25T12:15:32+00:00","dateModified":"2025-06-27T16:19:33+00:00","description":"Nuestra plataforma de opsina multicaracter\u00edstica (MCO) es la primera en demostrar, en ensayos cl\u00ednicos, la capacidad de restaurar la visi\u00f3n en pacientes con enfermedades retinianas y p\u00e9rdida visual severa. Nanoscope ha desarrollado MCO-010, la primera y \u00fanica tecnolog\u00eda optogen\u00e9tica de amplio espectro, respuesta r\u00e1pida y ultrasensible para la restauraci\u00f3n de la visi\u00f3n, independiente del gen.","breadcrumb":{"@id":"https:\/\/nanostherapeutics.com\/2024\/04\/25\/nanoscope-therapeutics-enhances-mutation-independent-retinal-gene-therapy-programs-with-appointment-of-allen-c-ho-md-as-chief-medical-advisor\/#breadcrumb"},"inLanguage":"es","potentialAction":[{"@type":"ReadAction","target":["https:\/\/nanostherapeutics.com\/2024\/04\/25\/nanoscope-therapeutics-enhances-mutation-independent-retinal-gene-therapy-programs-with-appointment-of-allen-c-ho-md-as-chief-medical-advisor\/"]}]},{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/nanostherapeutics.com\/2024\/04\/25\/nanoscope-therapeutics-enhances-mutation-independent-retinal-gene-therapy-programs-with-appointment-of-allen-c-ho-md-as-chief-medical-advisor\/#primaryimage","url":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2024\/04\/NSCOPE_LI_AllenHo_V3REV.jpg","contentUrl":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2024\/04\/NSCOPE_LI_AllenHo_V3REV.jpg","width":1200,"height":627},{"@type":"BreadcrumbList","@id":"https:\/\/nanostherapeutics.com\/2024\/04\/25\/nanoscope-therapeutics-enhances-mutation-independent-retinal-gene-therapy-programs-with-appointment-of-allen-c-ho-md-as-chief-medical-advisor\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/nanostherapeutics.com\/"},{"@type":"ListItem","position":2,"name":"Nanoscope Therapeutics Enhances Mutation-Independent Retinal Gene Therapy Programs with Appointment of Allen C. Ho, MD, as Chief Medical Advisor"}]},{"@type":"WebSite","@id":"https:\/\/nanostherapeutics.com\/#website","url":"https:\/\/nanostherapeutics.com\/","name":"Terap\u00e9utica del nanoscopio","description":"Recuperando la luz de la esperanza","publisher":{"@id":"https:\/\/nanostherapeutics.com\/#organization"},"alternateName":"Nanoscope Therapeutics","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/nanostherapeutics.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"es"},{"@type":"Organization","@id":"https:\/\/nanostherapeutics.com\/#organization","name":"Nanoscope Therapeutics, Inc","alternateName":"Nanoscope Therapeutics","url":"https:\/\/nanostherapeutics.com\/","logo":{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/nanostherapeutics.com\/#\/schema\/logo\/image\/","url":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2025\/03\/NSCOPE_Logo_Stack_2Color_512.png","contentUrl":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2025\/03\/NSCOPE_Logo_Stack_2Color_512.png","width":512,"height":435,"caption":"Nanoscope Therapeutics, Inc"},"image":{"@id":"https:\/\/nanostherapeutics.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/x.com\/NSTherapeutics","https:\/\/www.linkedin.com\/company\/nanoscope"]},{"@type":"Person","@id":"https:\/\/nanostherapeutics.com\/#\/schema\/person\/5aeedc9aef0946fe8f96f98f7b1808a2","name":"Terap\u00e9utica del nanoscopio"}]}},"_links":{"self":[{"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/posts\/5693","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/users\/6"}],"replies":[{"embeddable":true,"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/comments?post=5693"}],"version-history":[{"count":2,"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/posts\/5693\/revisions"}],"predecessor-version":[{"id":9049,"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/posts\/5693\/revisions\/9049"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/media\/5694"}],"wp:attachment":[{"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/media?parent=5693"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/categories?post=5693"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/tags?post=5693"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}